| |
|
Open Monoclonal Technology, Inc. ("OMT")
OMT is a private biotechnology company developing a new, fully human monoclonal
antibody (mAb) platform based on transgenic rats. The rat is a widely used laboratory animal with a well characterized immune system, a
nearly complete genome sequence, and established transgenesis and hybridoma technologies.
OMT’s founder, Dr. Roland Buelow, has twenty years of experience in the biotechnology field and is the inventor of numerous patents.
He was a founder of THP Inc. which developed genetically engineered rabbits expressing human antibodies. THP was acquired by Roche in 2007.
Antibodies are an important class of pharmaceutical products due to breakthroughs that have made them more human-like and eliminated unwanted
side effects.
Up until now, the genetically engineered mouse was the only animal-based human antibody platform available for developing new monoclonal antibodies. However, the mouse technology is expensive to license and has limited development options. With antibody sales expected to exceed $50 billion by 2013, there is an opportunity for OMT and its
new antibody platform with unrestricted development options.
OMT's antibody platform has freedom to operate and broad patent protection. |
|
| |
|
|
|
